Matches in SemOpenAlex for { <https://semopenalex.org/work/W3028308081> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W3028308081 endingPage "955" @default.
- W3028308081 startingPage "951" @default.
- W3028308081 abstract "Abstract Objectives Prader-Willi Syndrome (PWS) is characterised by hyperphagia often leading to obesity; a known risk factor for insulin resistance and type 2 (T2) diabetes. We present a prepubertal girl with PWS who developed diabetes. Case presentation Our case was diagnosed with PWS in infancy following investigation for profound central hypotonia and feeding difficulties. She commenced growth hormone (GH) aged 8 years for short stature and treatment improved linear growth. At age 12 years, she presented with polydipsia, polyuria and vulvovaginitis. She was overweight (BMI SDS +1.43). Diabetes was diagnosed (Blood glucose = 24.2 mmol/L, HbA1c = 121 mmol/mol or 13.2%). She was not acidotic and had negative blood ketones. Autoantibodies typical of type 1 diabetes were negative. She was initially treated with basal bolus insulin regime. GH was discontinued 3 months later due to concerns regarding GH-induced insulin resistance. Off GH, insulin requirements reduced to zero, allowing Metformin monotherapy. However off GH, she reported significant lethargy with static growth and increased weight. Combinations of Metformin with differing insulin regimes did not improve glucose levels. Liraglutide (GLP-1 agonist) and Metformin did not improve glucose levels nor her weight. Liraglutide and Empaglifozin (SGLT-2 inhibitor) therapy used in combination were well tolerated and demonstrated rapid normalisation of blood glucose and improvement in her HbA1c to within target (48 mmol/mol) which was sustained after 6 months of treatment. Conclusions Newer treatments for type 2 diabetes (e. g. GLP-1 agonists or SGLT-2 inhibitors) offer potential treatment options for those with diabetes and PWS when conventional treatments are ineffective." @default.
- W3028308081 created "2020-05-29" @default.
- W3028308081 creator A5011340845 @default.
- W3028308081 creator A5017633561 @default.
- W3028308081 creator A5040237112 @default.
- W3028308081 creator A5079030521 @default.
- W3028308081 creator A5079062528 @default.
- W3028308081 date "2020-05-24" @default.
- W3028308081 modified "2023-09-24" @default.
- W3028308081 title "Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report" @default.
- W3028308081 cites W1922423641 @default.
- W3028308081 cites W2077471693 @default.
- W3028308081 cites W2079252875 @default.
- W3028308081 cites W2142117907 @default.
- W3028308081 cites W2283618521 @default.
- W3028308081 cites W2325508263 @default.
- W3028308081 cites W2624032915 @default.
- W3028308081 cites W273266308 @default.
- W3028308081 cites W2752732025 @default.
- W3028308081 cites W2783907715 @default.
- W3028308081 cites W2788154323 @default.
- W3028308081 cites W4240242196 @default.
- W3028308081 doi "https://doi.org/10.1515/jpem-2019-0389" @default.
- W3028308081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32447330" @default.
- W3028308081 hasPublicationYear "2020" @default.
- W3028308081 type Work @default.
- W3028308081 sameAs 3028308081 @default.
- W3028308081 citedByCount "10" @default.
- W3028308081 countsByYear W30283080812020 @default.
- W3028308081 countsByYear W30283080812021 @default.
- W3028308081 countsByYear W30283080812022 @default.
- W3028308081 crossrefType "journal-article" @default.
- W3028308081 hasAuthorship W3028308081A5011340845 @default.
- W3028308081 hasAuthorship W3028308081A5017633561 @default.
- W3028308081 hasAuthorship W3028308081A5040237112 @default.
- W3028308081 hasAuthorship W3028308081A5079030521 @default.
- W3028308081 hasAuthorship W3028308081A5079062528 @default.
- W3028308081 hasConcept C126322002 @default.
- W3028308081 hasConcept C134018914 @default.
- W3028308081 hasConcept C2777180221 @default.
- W3028308081 hasConcept C2777391703 @default.
- W3028308081 hasConcept C2779306644 @default.
- W3028308081 hasConcept C2779624480 @default.
- W3028308081 hasConcept C2780180277 @default.
- W3028308081 hasConcept C2780323712 @default.
- W3028308081 hasConcept C2781308992 @default.
- W3028308081 hasConcept C555293320 @default.
- W3028308081 hasConcept C71924100 @default.
- W3028308081 hasConceptScore W3028308081C126322002 @default.
- W3028308081 hasConceptScore W3028308081C134018914 @default.
- W3028308081 hasConceptScore W3028308081C2777180221 @default.
- W3028308081 hasConceptScore W3028308081C2777391703 @default.
- W3028308081 hasConceptScore W3028308081C2779306644 @default.
- W3028308081 hasConceptScore W3028308081C2779624480 @default.
- W3028308081 hasConceptScore W3028308081C2780180277 @default.
- W3028308081 hasConceptScore W3028308081C2780323712 @default.
- W3028308081 hasConceptScore W3028308081C2781308992 @default.
- W3028308081 hasConceptScore W3028308081C555293320 @default.
- W3028308081 hasConceptScore W3028308081C71924100 @default.
- W3028308081 hasIssue "7" @default.
- W3028308081 hasLocation W30283080811 @default.
- W3028308081 hasOpenAccess W3028308081 @default.
- W3028308081 hasPrimaryLocation W30283080811 @default.
- W3028308081 hasRelatedWork W138803513 @default.
- W3028308081 hasRelatedWork W1772468801 @default.
- W3028308081 hasRelatedWork W1979258691 @default.
- W3028308081 hasRelatedWork W1986132654 @default.
- W3028308081 hasRelatedWork W2010140898 @default.
- W3028308081 hasRelatedWork W2082140668 @default.
- W3028308081 hasRelatedWork W2217841699 @default.
- W3028308081 hasRelatedWork W2326602311 @default.
- W3028308081 hasRelatedWork W2744240433 @default.
- W3028308081 hasRelatedWork W4234612679 @default.
- W3028308081 hasVolume "33" @default.
- W3028308081 isParatext "false" @default.
- W3028308081 isRetracted "false" @default.
- W3028308081 magId "3028308081" @default.
- W3028308081 workType "article" @default.